Lämpimästi tervetuloa FICAN science webinaariin keskiviikkona 21.5 klo 15-16!

Puhujana: Professori ja Eturauhassyövän tutkimuskeskuksen johtaja Anssi Auvinen, Tampereen yliopisto

Aiheena: A randomised pragmatic population-based trial of prostate cancer screening
(ProScreen)

Tutustu puhujaan: Epidemiologia, Tampereen yliopisto

Tällä kertaa webinaarin järjestää Sisä-Suomen syöpäkeskus – FICAN Mid
Webinaari pidetään verkossa (Microsoft Teams), johon voit liittyä suoraan tästä linkistä:

Liity webinaariin tästä / Join the webinar here

Ohessa englanninkielinen tiivistelmä ja lähteet.

Abstract:
We have shown in the ERSPC trial that PSA-based screening can reduce prostate cancer mortality, but due to extensive overdiagnosis of low-risk cases, the balance of benefits and harms is questionable.

We have designed a screening protocol aimed at minimising overdiagnosis, but maintaining the mortality impact. The screening intervention consist of three tests, provided in a stepwise fashion: First PSA, for men with PSA3 ng/ml also a kallikrein panel (4Kscore) and if it exceeds 7.5%, a referral to MRI. Men with a suspicious MRI findings (PI-RADS score 3–5) are referred to targeted prostate biopsy.

We have randomised 113,357 men aged 50–63 from Helsinki and Tampere metropolitan areas, with a quarter allocated to screening and the rest to the control arm.
Results from the first screening round show that large majority (80%) of the screen-detected cases are high-grade cancers (ISUP grade group 2–5). Compared with the control arm, one additional high-grade cancer was detected per 200 men, while the excess of low-grade cases (grade group 1) was considerably smaller (one excess case per 800 men).

Relevat references for this talk:

  • Auvinen A, Tammela T, Mirtti T, et al. Prostate cancer screening with PSA, kallikrein panel and MRI: The ProScreen randomized trial. JAMA 2024;331:1452-59
  • Rannikko A, Leht M, Mirtti T, ym. Population-based randomized trial of screening for clinically significant prostate cancer: A pilot study. BJU Int 2022;130:193-199
  • Bratt O, Auvinen A, Godtman AR, ym. Screening for prostate cancer. BMJ Oncol 2023;2:e000039